AbbVie has agreed to acquire Apogee Therapeutics in a cash deal valued at about $10.9 billion, according to multiple reports. The acquisition is described as AbbVie’s largest deal in more than half a decade and as part of a broader wave of mergers in the biopharmaceutical sector.
The companies’ deal centers on strengthening AbbVie’s biopharmaceutical pipeline, particularly in areas related to immunology and inflammation. Bloomberg also notes the transaction would expand AbbVie’s dermatology presence by adding potential treatments for atopic dermatitis, commonly referred to as eczema.
STAT reports that Apogee is developing an experimental atopic dermatitis drug and that the acquisition is priced at nearly $11 billion. The Wall Street Journal and Financial Times similarly frame the purchase as a way for AbbVie to broaden its immunology and inflammation portfolio.
All accounts agree on the core terms: the buyer is AbbVie, the target is Apogee Therapeutics, and the consideration is approximately $10.9 billion paid in cash. Details beyond valuation and strategic rationale are not provided in the excerpts.
